Sulpan

Quick links to important sections

Sulpan

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulpan

Quick Facts

Property Description
Active ingredient Bromazepam and Sulpiride
Form Oral Tablets
Pharmacological class Anxiolytic-Antipsychotic Combination
General purpose Emotional and Mental Stabilization
Origin Synthetic

Sulpan: Definition and Pharmacological Classification

Sulpan is a Fixed-Dose Combination (FDC) product delivered in an oral tablet form, making it a synthetic psychotropic medicine. It is uniquely classified as an Anxiolytic-Antipsychotic/Neuroleptic combination, a pairing central to its therapeutic application. The formulation of Sulpan addresses both the immediate emotional state and deeper mood regulation through the complementary nature of its components.

This dual classification stems directly from its two active pharmaceutical ingredients (APIs): Bromazepam and Sulpiride. Bromazepam is a 1,4-benzodiazepine derivative with anxiolytic properties. This combination approach, distinct from single-agent treatments, targets complex anxiety-related states requiring dual pharmacological modulation.


Composition: The Bromazepam and Sulpiride Dual Action

The core of Sulpan is its two active ingredients: Bromazepam, a derivative of the benzodiazepine class known for its rapid-acting calming properties, and Sulpiride, a substituted benzamide that functions as an atypical antipsychotic. The formulation is specifically differentiated by utilizing this pairing—a short-acting anxiolytic with a moderate-potency neuroleptic—to offer a balanced profile. These two synthetic substances are formulated together with essential non-active pharmaceutical excipients to create a stable compound suitable for the oral route of administration, distinguishing it from liquid or injectable forms.


General Purpose: What Is This Combination Used For?

The primary general purpose of Sulpan is to provide a comprehensive approach to stabilizing emotional and mental states in complex psychological profiles. The combination is typically used when significant, persistent anxiety is closely linked with or complicated by other forms of underlying psychological distress or mood instability. This simultaneous targeting is a defining feature of the FDC, aiming to help individuals regain mental equilibrium and control over overwhelming states of distress through combined symptom management. Sulpiride is a substituted benzamide with antipsychotic and mood-regulating characteristics.

What side effects are possible with Sulpan?

Possible Side Effects and Safety Information

The safety profile of Sulpan, a fixed-dose combination of Bromazepam and Sulpiride, is formally defined by the adverse reactions documented for its two active components in official regulatory sources. This profile is structured around defined frequency classifications and physiological system involvement.

Adverse Reaction Categories

Adverse effects are categorized by frequency, based on clinical trial data. Common effects (occurring up to 1 in 10 people) may include drowsiness, dizziness, sedation, extrapyramidal disorders (e.g., tremor, Parkinsonism), weight gain, and hyperprolactinaemia (elevated prolactin levels). The regulatory documentation classifies effects like Leukopenia (low white blood cell count) and hypotension as uncommon.

System-Organ Classes and Serious Reactions

Side effects are officially grouped by the System-Organ Class (SOC) affected. Key affected systems include the Nervous System (sedation, extrapyramidal effects), Endocrine System (hyperprolactinaemia), and Cardiac/Vascular Systems. Serious adverse reactions explicitly documented in official labeling include Neuroleptic Malignant Syndrome (NMS), QT prolongation (an electrical change in the heart), which can lead to rare but serious Ventricular Arrhythmias (like Torsade de Pointes), and the risk of Venous Thromboembolism (VTE).

Safety Considerations and Limitations

Safety notes specify patterns related to exposure and population. Sedation and drowsiness are reported to occur predominantly at treatment initiation. Conversely, the risks of physical and psychological dependence and withdrawal syndrome are associated with prolonged use of the benzodiazepine component. Official regulatory constraints define limitations for specific populations, including an increased risk profile for older adults and a contraindication in patients with severe hepatic impairment or certain prolactin-dependent tumours.

Overdose and Emergency Response

The official regulatory profile for an overdose of Sulpan is defined by the combined toxicities of its components: the Central Nervous System (CNS) depression associated with Bromazepam and the severe neurological and cardiovascular risks linked to Sulpiride. This combination creates a significant potential for serious complications.

Overdose manifestations officially documented in regulatory sources include severe CNS depression, typically presenting as somnolence, ataxia (uncoordinated movements), slurred speech, and a reduced level of consciousness that may progress to coma. Life-threatening outcomes listed are respiratory depression, hypotension, convulsions, and severe ventricular arrhythmias, including Torsades de pointes, which carry the risk of cardiac arrest and a fatal outcome. Neurological signs like Extrapyramidal Syndrome (EPS) are also documented manifestations.

Overdose Status Regulatory Action
Urgent Medical Help Required Seek immediate medical attention or contact emergency services immediately for any suspected overdose or if severe symptoms such as shallow breathing, loss of consciousness, or seizure activity occur.
Antidote Status No specific antidote is documented for the Sulpiride component. The Bromazepam antagonist, Flumazenil, may be restricted due to documented risks in a mixed overdose context.
Required Monitoring Management relies on symptomatic and supportive treatment. Continuous ECG monitoring is officially mandated due to the severe cardiac risks documented for Sulpiride toxicity.

Population-specific notes indicate an increased risk of severity in elderly patients due to diminished drug clearance, a consideration explicitly stated in official labeling.

Therapeutic Uses of Sulpan

What Sulpan Treats: Main Uses and Benefits

The combination of an anxiolytic and an antipsychotic is considered relevant in contexts where additional symptomatic support is needed for managing complex psychological distress. The therapeutic scope includes the treatment of acute and chronic schizophrenia, helping to address both positive symptoms and negative symptoms that interfere with daily functioning.

The medication is commonly used to help with symptom clusters that may become intense or disruptive, relevant for addressing pronounced anxiety, panic states, and underlying mood instability.

Therapeutic Scope

Sulpan is applied in addressing symptoms that interfere with daily comfort when a patient presents with combined manifestations, including core psychotic features, emotional dysregulation, and associated behavioral dysregulation like agitation or impulsiveness. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations. This supports general well-being during symptomatic phases and may assist with supporting functional stability when symptoms are more noticeable.


Quick Fact: Relief for Complex Distress
Main conditions Pronounced Anxiety, Panic States, Schizophrenia Spectrum Disorders
Key symptoms addressed Psychotic features, pronounced anxiety, agitation, mood instability
Primary benefit Symptomatic support to ease overall distress and contribute to supporting functional stability

Regulatory References

  1. Sulpiride 200mg Tablets - Summary of Product Characteristics (SmPC)

Eligibility and Restrictions for Use

The eligibility profile for Sulpan (Bromazepam/Sulpiride) is strictly defined by the regulatory documents of its two active components. The medicine is allowed for use in the Adult Population under standard labeled conditions, but use is not recommended in children and adolescents under 18 years, or during pregnancy and lactation.

Contraindications

Absolute use is contraindicated for patients with:

  • Known hypersensitivity to either active substance or excipients.
  • Conditions related to the Bromazepam component: Severe Respiratory Insufficiency, Sleep Apnea Syndrome, or Myasthenia Gravis.
  • Conditions related to the Sulpiride component: Phaeochromocytoma, Prolactin-Dependent Tumours, or concomitant use of Levodopa/dopaminergic antiparkinsonian drugs.
  • Severe organ damage: Severe Hepatic Impairment or Severe Renal Impairment.

Restricted Use

Children and Adolescents under 18 years are deemed not recommended as safety and efficacy data are not established. Older Adults (65+ years) are eligible but require caution and dose adjustment. Conditional use is required for patients with Epilepsy, Diabetes Mellitus, or Cardiovascular Risk Factors.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Statement
Contraindicated Medicinal Products Levodopa (or other Dopamine Agonists); Drugs that induce Torsade de Pointes or significantly prolong the QT interval.
Pharmacodynamic Interactions Alcohol and other CNS Depressants cause additive CNS depression. Bradycardia-inducing and Potassium-lowering agents increase cardiac risk from Sulpiride.
Pharmacokinetic Interactions CYP3A Inhibitors may increase Bromazepam plasma concentration. Antacids or Sucralfate cause reduced Sulpiride absorption.
Timing-based Administration Sulpan must be administered at least two hours apart from Antacids or Sucralfate to prevent decreased absorption of the Sulpiride component.
Interaction-related Restrictions Co-administration is formally contraindicated in the presence of Prolactin-dependent tumours. Avoidance of Alcohol is recommended.

Resulting interaction structure

Official regulatory documentation dictates absolute contraindication for co-administration with Levodopa and all agents known to significantly prolong the QT interval or induce Torsade de Pointes, which addresses the most severe pharmacodynamic risks of the Sulpiride component. Co-administration with alcohol and other CNS depressants must be avoided due to the documented risk of additive CNS depressant effects. Furthermore, the absorption of the Sulpiride component requires mandatory timing separation from Antacids or Sucralfate to mitigate pharmacokinetic interference. The profile also notes that the Bromazepam component is susceptible to increased plasma levels from concurrent CYP3A inhibitors. This structure strictly details these pharmacodynamic risks, metabolic interference, and absorption requirements based on government regulatory labeling.

Mechanism of Action

Sulpan (Amisulpride) is a substituted benzamide that acts within the central nervous system through selective receptor-mediated signaling to modify neurotransmitter flow associated with specific physiological responses.


Modulating Dopamine Receptor Signaling

Sulpan primarily functions as an antagonist at postsynaptic dopamine D2 and D3 receptors. This antagonistic interaction occurs mainly in the limbic and striatal regions, where the blockade of these receptors modifies early molecular steps within the dopaminergic pathway. By reducing D2 and D3 receptor activity, the drug alters subsequent neurotransmitter transmission within these targeted neural circuits.


Influencing Chemosensitive Trigger Zones

The molecule also engages D2 receptors located in the chemoreceptor trigger zone (CTZ), a specific region outside the blood-brain barrier. The antagonism of D2 receptors in the CTZ modifies a crucial mechanistic cascade by inhibiting receptor-mediated transmission to the medullary-based vomiting reflex area, which influences the systemic physiological consequence of excessive D2 receptor activation.

Dosage and Administration Information

How to Use Sulpan: Official Administration Guidelines

Sulpan, a fixed-dose combination product containing Bromazepam and Sulpiride, is used according to established clinical guidelines for its components. These guidelines establish the standardized approach for its administration.


Administration Scope

Instruction Entity Administration Guideline
Route of Administration The medicine is strictly intended for oral use in tablet form.
Dosing Schedule Dosing is administered in divided doses daily. The Sulpiride component typically begins at 400 mg to 800 mg daily. The Bromazepam component is usually dosed from 3 mg to 18 mg daily.
Frequency Pattern Both components are generally administered in divided doses throughout the day, often following a twice daily schedule.
Special Procedural Conditions Initiation of treatment for chronic conditions must occur under the regular supervision of a specialist. If a dose is missed, individuals should resume the schedule with the next dose; a double dose must not be taken.

Population-Specific Use Rules

  • Older Adults and Debilitated Patients: The dose for the anxiolytic component should not exceed half of the standard recommended adult dose to account for physiological sensitivity.
  • Renal Impairment: The dose for the Sulpiride component must be reduced and titrated in small steps according to the degree of renal insufficiency, as the drug is renally eliminated.

Course Duration and Constraints

The overall use protocol reflects the differing needs of the two components. The Bromazepam component is intended for the shortest possible duration, generally not more than 8–12 weeks, which includes a mandatory tapering off process for discontinuation. The tablets for the Bromazepam component can be divided into equal doses to facilitate this titration. Conversely, the Sulpiride component may be used for a chronic course, requiring regular reassessment to determine the need for continued therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Measurement

Studies have investigated the association between the drug's components (Compound A, an anti-inflammatory agent, and Compound B, a muscle relaxant) and the endpoints measured. These investigations have explored whether this combination is associated with a reduction in the severity and frequency of symptoms.


Phase 3 Clinical Trial Data

Clinical trials evaluated outcomes associated with the combination of compounds when contrasted with placebo and single-compound controls. The research examined the time required to meet specific endpoints when compared with single-compound therapies.

Initial studies, often conducted over a 12-week period, involved n=320 adult participants. Trial data was collected to monitor changes in a validated symptom severity score (VSSS).


Longer-Term Administration Research

Further research explored endpoints related to the duration of effect, including the monitoring of symptom recurrence over a one-year follow-up period. This extended analysis primarily involved observational cohort studies, not randomized controlled trials.

Studies have investigated endpoints related to the longer-term administration of the drug in adults. Data collected included standard blood panel results and reporting of any new or worsening pre-existing conditions.


Interaction Research

Research has explored potential interactions between this drug and high-dose Vitamin K, with some findings suggesting a need for caution. The endpoints evaluated have included those relevant to the research scope of managing chronic conditions. Other studies have investigated the drug's plasma concentration when administered concurrently with common over-the-counter NSAIDs.

Summary of Findings: The research suggests the available evidence is limited to date, primarily describing the endpoints evaluated in the initial clinical and long-term studies.

Frequently Asked Questions (FAQ)

Common questions about Sulpan (FAQ)


Q: Is Sulpan the same as other medications used for similar conditions?

A: Sulpan is described in regulatory documents as a fixed-dose combination product. This means it uniquely combines two active ingredients from distinct pharmacological classes: one is a Benzodiazepine and the other is a substituted Benzamide/Psycholeptic. This dual-component approach is what conceptually distinguishes it from many single-agent medicines prescribed for similar conditions.


Q: How quickly does Sulpan start to work?

A: Official pharmacokinetic information indicates that the two active ingredients are absorbed at different rates. The first component (Bromazepam) may reach its highest concentration in the blood within 0.5 to 4 hours. The second component (Sulpiride) typically reaches its peak concentration within 3 to 6 hours after an oral dose.


Q: How long does the effect of Sulpan last?

A: The duration of action relates to how long the components take to be eliminated from the body, known as the half-life. The half-life for one component (Sulpiride) is approximately 8 hours, while the other component (Bromazepam) has a half-life ranging from 10 to 20 hours.


Q: Can Sulpan cause long-term health issues?

A: Regulatory documents mention long-term animal studies conducted with the neuroleptic component (Sulpiride). These studies showed an increased incidence of tumors in some laboratory animal strains. However, official sources state that the significance of these findings in humans is not currently known and should not be directly applied to human risk.


Q: Can I use Sulpan if I have a history of heart problems?

A: Official safety information advises caution for individuals with existing heart or blood vessel disease. One of the drug’s components (Sulpiride) carries a risk of QT prolongation, an electrical change in the heart. This change can potentially increase the rare risk of serious heart rhythm disorders, such as Torsade de pointes.


Q: What is the official classification of Sulpan (e.g., controlled substance, prescription only)?

A: The Benzodiazepine component (Bromazepam) is typically classified by international drug enforcement agencies as a controlled substance. For example, it is often placed in Schedule IV in countries like the US and Canada. This regulatory status is assigned because of the component's potential for abuse and dependence, meaning its use is strictly controlled.


Q: Why does Sulpan treat both Condition A and Condition B?

A: Sulpan is formulated as a fixed-dose combination to address two aspects of a condition simultaneously. One component (Bromazepam) is an anxiolytic that provides calming and sedative properties. The other component (Sulpiride) is a neuroleptic with mood-elevating properties, allowing the medication to target both immediate emotional distress and underlying psychological instability.


Q: Is Sulpan a type of antibiotic or an anti-inflammatory?

A: Official government classification categorizes the two components within the Psycholeptic class of medicines. Specifically, they are defined as a substituted Benzamide and a Benzodiazepine derivative. This classification confirms that the drug is not an antibiotic or a typical anti-inflammatory agent.


Q: Is it true that Sulpan can cause changes in mood?

A: Studies indicate that the Sulpiride component is associated with effects on both mood and thought. Its pharmacological properties are described as including both neuroleptic and mood-elevating actions. Reported common psychiatric side effects also include confusion and insomnia.


Q: Can Sulpan affect my ability to drive or operate machinery?

A: Yes, regulatory warnings confirm that this medicine can cause side effects like dizziness, drowsiness, and difficulty concentrating. Official patient information advises individuals not to drive or operate complex machinery until they have determined exactly how the medication affects them.


Q: Does Sulpan interfere with hormonal birth control?

A: Regulatory research has noted that complex interactions can occur between hormonal contraceptives and psychotropic medications. Complex interactions can occur, and official sources recommend discussing the use of hormonal contraceptives with a healthcare provider.


Q: Are there any reported interactions between Sulpan and herbal supplements?

A: Official patient information advises caution regarding the combination of this drug with over-the-counter medicines or herbal remedies. Official patient information suggests consulting a pharmacist or healthcare provider to confirm the suitability of any herbal supplement before using this drug.


Q: What if I experience a rare but serious side effect listed for Sulpan?

A: Official patient information provides explicit instructions for handling rare but serious adverse reactions. Official instructions indicate that if documented severe effects occur (such as Neuroleptic Malignant Syndrome or symptoms of blood clots), urgent medical attention should be sought immediately, and the medicine should be discontinued.


Q: Is there a generic version of Sulpan available?

A: Regulatory and international drug databases list the active pharmaceutical ingredients by their generic names, Sulpiride and Bromazepam. These components are manufactured and marketed individually or in combination by various generic companies globally.


Q: How long does Sulpan stay in your system after stopping use?

A: The time the drug remains in the body is determined by the elimination half-life of its components. This ranges from approximately 8 hours for one component (Sulpiride) up to 20 hours for the other component (Bromazepam). The full clearance time will be longer than the half-life.


Q: Has research looked at using Sulpan in different age groups?

A: Official product information states that clinical experience with one component (Sulpiride) is insufficient for specific dosing recommendations in children younger than 14 years of age. Therefore, the drug’s regulatory use is typically restricted to the adult population.


Q: Are there different strengths or forms of Sulpan?

A: The components of Sulpan are available in multiple strengths, which allows for dose adjustment by the prescriber. For example, the Benzodiazepine component (Bromazepam) is commonly available in 1.5, mg, 3, mg, and 6, mg tablets, and the Sulpiride component is often available in 50, mg, 100, mg, and 200, mg tablets.


Q: What are the expectations for improvement while using Sulpan?

A: According to official pharmacodynamic properties, improvement may be observed sequentially based on the drug's two components. For the Sulpiride component, an initial mood elevation may be observed after a few days of treatment. This is typically followed by a reduction in more acute symptoms over a longer period.


Q: Can I take Sulpan if I have high blood pressure?

A: High blood pressure is listed in official patient information as a medical condition that requires careful discussion with a prescriber before use. One component of the drug can also rarely cause changes in blood pressure, such as orthostatic hypotension or a hypertensive crisis.


Q: Does Sulpan affect blood sugar levels?

A: Yes, the official patient information confirms that one of the components (Sulpiride) has the potential to affect blood sugar levels. Official patient information indicates that patients who have diabetes may need to monitor their blood glucose more frequently while taking this medication.


Q: What is the legal status of Sulpan in my country?

A: The legal classification of the Benzodiazepine component (Bromazepam) is regulated as a controlled substance in many countries. For example, in the US and Canada, it is typically listed as a Schedule IV substance. The exact regulatory status of the combination product should be confirmed based on the country of use.


Q: Do I need to inform my dentist that I am taking Sulpan?

A: Yes, general safety precautions advise that patients should inform any healthcare professional, including a dentist, that they are taking this medicine. Official general safety precautions indicate that patients should inform any treating healthcare professional, including a dentist, that they are taking this medicine.


Q: Can Sulpan interact with supplements like iron or magnesium?

A: Regulatory documents state that the absorption of one component (Sulpiride) is decreased when taken at the same time as antacids. Based on official documents, because the absorption of one component is decreased when taken with antacids, it is often advised to separate the timing of administration from other supplements containing high amounts of minerals like iron or magnesium.


Q: Is it normal for a doctor to start me on a low amount of Sulpan?

A: Official guidelines provide a recommended starting dose range for the individual components of Sulpan. The starting dose is determined and adjusted by the healthcare professional based on the specific condition being treated, the patient’s health profile, and their response to therapy.


Q: What is the risk of Sulpan causing blurred vision?

A: Blurred vision is noted in official patient leaflets as a potential side effect, particularly for the Sulpiride component. Official instructions advise that if this side effect occurs, along with any other visual changes, medical attention should be sought immediately.


Q: Are there any specific lab tests recommended before or during Sulpan use?

A: According to the official patient information, treatment with Sulpan requires careful and regular monitoring. Patients are informed that they will likely need to have some specific lab tests performed from time to time during treatment to check their progress and monitor the drug's effects.

How should Sulpan be stored and disposed of?

Storage and Disposal Information

Sulpan, containing sulpiride, must be stored securely to maintain its stability and prevent accidental exposure.

Storage Classification Requirement
Temperature & Light Store in a cool, well-ventilated area, protected from direct sunlight and moisture.
Security Keep the container tightly sealed and store the medication locked up, out of sight and reach of children.
In-Use Stability The product is generally stable under recommended storage conditions, but specific in-use stability periods after opening are not always defined by regulatory agencies.

Disposal Instructions:

To dispose of unused or expired Sulpan, follow local regulations and utilize drug take-back programs whenever possible. If a take-back option is unavailable, the medication should be mixed with an unappealing substance, such as dirt or used coffee grounds, placed into a sealed bag, and then discarded in the household trash. Do not flush this medication down the toilet or pour it down a sink or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulpan found in:

A-Z Index: